Abstract: One embodiment of the present invention provides a detection kit for detecting c-Met gene expression, wherein the detection kit includes a primer set which is specifically bound to the c-Met gene; and a cleavable probe which is specifically bound to the inside of a c-Met gene amplification product which is amplified by the primer set. Another embodiment of the present invention provides a method of measuring the c-Met gene expression by using the detection kit according to one embodiment of the present invention. The method according to one embodiment of the present invention is used to efficiently detect a low concentration of c-Met gene expression for cancer diagnosis and prognosis diagnosis.

Abstract: A screening method is described for selecting patient-specific anti-cancer agents reflecting individual genetic properties, in a precise and rapid manner, using an extremely small amount of cancer cells. Such screening method is useful for development of novel anti-cancer agents and the personalized medical field.

Abstract: A cell analysis apparatus may include: an image processing unit imaging cultured cell colonies to convert the imaged cell colonies into digital signals; an outline extracting unit extracting outlines of the cell colonies from image data obtained from the image processing unit; a size calculating unit calculating sizes of the cell colonies from the extracted outlines; and a selecting unit comparing the sizes of the cell colonies with a preset value to select grown cell colonies.

Abstract: One embodiment of the present invention provides a detection kit for detecting a chronic myelogenous leukemia (CML) gene expression, wherein the detection kit includes a primer set which is specifically bound to the CML gene; and a cleavable probe which is specifically bound to the inside of a CML gene amplification product which is amplified by the primer set. Another embodiment of the present invention provides a method of measuring the CML gene expression by using the detection kit according to one embodiment of the present invention. The method according to one embodiment of the present invention is used to efficiently detect a low CML gene expression for CML diagnosis and prognosis diagnosis.

Abstract: The present invention relates to stem cells in which a gene that activates signaling is introduced and to a method for proliferating the stem cells. More specifically, the invention relates to a method of significantly increasing the ability of stem cells to proliferate, either by transfecting stem cells with the Notch intracellular domain (NICD) to activate the Notch signaling pathway, or by transfecting stem cells with the c-MET gene and treating the transfected stem cells with the HGF ligand protein to activate the c-MET/HGF signaling pathway. According to the present invention, as a result of activating the Notch signaling pathway or the c-MET/HGF signaling pathway, stem cells having an excellent ability to proliferate can be produced in large amounts. Particularly, since neural stem cells which have been difficult to culture in vitro can be proliferated in large amounts, thus the neural stem cells will be more useful for the preparation of cell therapeutic agents for treating cranial nerve diseases.

Abstract: 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy.

Abstract: The present disclosure relates to a method for more easily and economically producing a selenophene-fused aromatic compound derivative containing various substituents and the selenophene-fused aromatic compound produced according to the method, and the selenophene-fused aromatic compound can be used for various purposes such as an intermediate of an anti-bacterial or anticancer substance, an indicator of which color is changed depending on a solvent, or a fluorescent substance.

Abstract: The present invention relates to a system for screening personalized anticancer agents, a method for screening personalized anticancer agents using the system, and an apparatus for screening personalized anticancer agents. When the inventive system for screening personalized anticancer agents is used, an anticancer agent showing an optimal anticancer activity against cancer cells collected from a patient can be selected from a variety of anticancer agents, and it is possible to previously examine a therapeutic response that can appear when the selected anticancer agent is administered into the patient. Thus, the risk of trial and error in cancer therapy can be reduced, and the cost and time required for cancer therapy can be reduced.

Abstract: The antibody of the invention has high specificity to human c-Met and is cross-reactive to mouse c-Met. The antibody or its antigen-binding fragment of the invention is capable of specifically binding to human c-Met as well as mouse c-Met, more accurate preclinical results can be confirmed in the efficacy evaluation using mouse tumor models. The antibody of the invention inhibits the growth of cancer cells derived from various cancers by a considerable binding affinity to c-Met and the suppression of c-Met function therefrom, inhibits the phosphorylation of c-Met and downstream signaling molecules to suppress c-Met signaling, and inhibits neovascularization, thereby being very efficient in the prevention and treatment of cancers.

Abstract: 7-(3-Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy.

Abstract: A cell analysis apparatus may include: an image processing unit imaging cultured cell colonies to convert the imaged cell colonies into digital signals; an outline extracting unit extracting outlines of the cell colonies from image data obtained from the image processing unit; a size calculating unit calculating sizes of the cell colonies from the extracted outlines; and a selecting unit comparing the sizes of the cell colonies with a preset value to select grown cell colonies.

Abstract: The present disclosure relates to a novel method for preparing selenyl-substituted aromatic aldehyde compounds by forming a selenolate nucleophile and performing a nucleophilic substitution reaction between the selenolate nucleophile and an aromatic aldehyde starting material.

Abstract: One embodiment of the present invention provides a detection kit for detecting c-Met gene expression, wherein the detection kit includes a primer set which is specifically bound to the c-Met gene; and a cleavable probe which is specifically bound to the inside of a c-Met gene amplification product which is amplified by the primer set. Another embodiment of the present invention provides a method of measuring the c-Met gene expression by using the detection kit according to one embodiment of the present invention. The method according to one embodiment of the present invention is used to efficiently detect a low concentration of c-Met gene expression for cancer diagnosis and prognosis diagnosis.

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of cancer or Temodal resistant glioblastoma multiform comprising azathioprine as an active ingredient. The azathioprine of the present invention is not only effective in inhibiting the growth of glioblastoma multiform, a kind of brain tumor, but also excellent in treating glioblastoma multiform that displays resistance against Temodal (temozolomide), the conventional therapeutic agent for glioblastoma multiform, so that it can be effectively used as an active ingredient of a pharmaceutical composition for the prevention or treatment of such cancer as brain tumor (particularly, glioblastoma multiform) and particularly Temodal resistant glioblastoma multiform.

Abstract: Provided is a method for producing a glioblastoma mouse model and the mouse model produced thereby, the method including the steps of: (a) dividing a glioblastoma tissue, isolated from a patient, into 4 or more sections, and collecting one or more pieces from each of the sections; (b) dissociating a mixture of the collected pieces into glioblastoma cells as single cells; and (c) orthotopically transplanting a graft sample containing the glioblastoma cells obtained in step (b), into the brain of an immunodeficient mouse. Further provided are a method of screening a glioblastoma therapeutic agent using the mouse model and a method of providing information for selection of a patient-specific glioblastoma therapy using the mouse model. The glioblastoma mouse model shows the same genetic, morphological and pathological characteristics as those of the parental tumor, and it allows screening patient-specific glioblastoma therapeutic agent or selecting safer and more effective patient-specific glioblastoma therapy.

Abstract: A screening method is described for selecting patient-specific anti-cancer agents reflecting individual genetic properties, in a precise and rapid manner, using an extremely small amount of cancer cells. Such screening method is useful for development of novel anti-cancer agents and the personalized medical field.

Abstract: The present invention relates to a stem cell culture medium which can be substituted for a conventional stem cell culture medium containing the heterologous protein fetal bovine serum, and more particularly to a stem cell culture medium containing a basal medium and a knockout serum replacement and a method of culturing stem cells using the same. According to the invention, a high purity of stem cells having a reduced ability to spontaneously differentiate can be obtained without having to use the heterologous protein fetal bovine serum and expensive growth factors (EGF and bFGF), and thus the efficacy of stem cell therapy can be significantly increased.

Abstract: One embodiment of the present invention provides a detection kit for detecting a chronic myelogenous leukemia (CML) gene expression, wherein the detection kit includes a primer set which is specifically bound to the CML gene; and a cleavable probe which is specifically bound to the inside of a CML gene amplification product which is amplified by the primer set. Another embodiment of the present invention provides a method of measuring the CML gene expression by using the detection kit according to one embodiment of the present invention. The method according to one embodiment of the present invention is used to efficiently detect a low CML gene expression for CML diagnosis and prognosis diagnosis.

Abstract: The present invention relates to stem cells in which a gene that activates signaling is introduced and to a method for proliferating the stem cells. More specifically, the invention relates to a method of significantly increasing the ability of stem cells to proliferate, either by transfecting stem cells with the Notch intracellular domain (NICD) to activate the Notch signaling pathway, or by transfecting stem cells with the c-MET gene and treating the transfected stem cells with the HGF ligand protein to activate the c-MET/HGF signaling pathway. According to the present invention, as a result of activating the Notch signaling pathway or the c-MET/HGF signaling pathway, stem cells having an excellent ability to proliferate can be produced in large amounts. Particularly, since neural stem cells which have been difficult to culture in vitro can be proliferated in large amounts, thus the neural stem cells will be more useful for the preparation of cell therapeutic agents for treating cranial nerve diseases.

Abstract: The antibody of the invention has high specificity to human c-Met and is cross-reactive to mouse c-Met. The antibody or its antigen-binding fragment of the invention is capable of specifically binding to human c-Met as well as mouse c-Met, more accurate preclinical results can be confirmed in the efficacy evaluation using mouse tumor models. The antibody of the invention inhibits the growth of cancer cells derived from various cancers by a considerable binding affinity to c-Met and the suppression of c-Met function therefrom, inhibits the phosphorylation of c-Met and downstream signaling molecules to suppress c-Met signaling, and inhibits neovascularization, thereby being very efficient in the prevention and treatment of cancers.